AMELIA LAMMERS: Open Payments
NPI 1558807669 · MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$378 in 19 payments from 9 companies in 2025. Trend: 2023 $267 · 2024 $149 · 2025 $378
Food & beverage: $378
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $73 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $62 |
| Lilly USA, LLC | 3 | $60 |
| Novo Nordisk Inc | 3 | $54 |
| Novartis Pharmaceuticals Corporation | 2 | $47 |
| Kerecis Limited | 1 | $24 |
| Biofrontera Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
Products named: OTEZLA, COSENTYX, ILUMYA, MOUNJARO, Kerecis SurgiClose, AMELUZ, Leqselvi, Wegovy.
Industry payments across FL — which companies pay providers there.
